Literature DB >> 11082444

Stimulus-dependent modulation of [(3)H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin.

D J Dooley1, C M Donovan, T A Pugsley.   

Abstract

Gabapentin (GBP; Neurontin) has proven efficacy in several neurological and psychiatric disorders yet its mechanism of action remains elusive. This drug, and the related compounds pregabalin [PGB; CI-1008, S-(+)-3-isobutylgaba] and its enantiomer R-(-)-3-isobutylgaba, were tested in an in vitro superfusion model of stimulation-evoked neurotransmitter release using rat neocortical slices prelabeled with [(3)H]norepinephrine ([(3)H]NE). The variables addressed were stimulus type (i.e., electrical, K(+), veratridine) and intensity, concentration dependence, onset and reversibility of action, and commonality of mechanism. Both GBP and PGB inhibited electrically and K(+)-evoked [(3)H]NE release, but not that induced by veratridine. Inhibition by these drugs was most pronounced with the K(+) stimulus, allowing determination of concentration-effect relationships (viz., 25 mM K(+) stimulus: GBP IC(50) = 8.9 microM, PGB IC(50) = 11.8 microM). R-(-)-3-Isobutylgaba was less effective than PGB to decrease stimulation-evoked [(3)H]NE release. Other experiments with GBP demonstrated the dependence of [(3)H]NE release inhibition on optimal stimulus intensity. The inhibitory effect of GBP increased with longer slice exposure time before stimulation, and reversed upon washout. Combination experiments with GBP and PGB indicated a similar mechanism of action to inhibit K(+)-evoked [(3)H]NE release. GBP and PGB are concluded to act in a comparable, if not identical, manner to preferentially attenuate [(3)H]NE release evoked by stimuli effecting mild and prolonged depolarizations. This type of modulation of neurotransmitter release may be integral to the clinical pharmacology of these drugs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11082444

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  48 in total

Review 1.  Calcium channel alpha2delta subunits: differential expression, function, and drug binding.

Authors:  Norbert Klugbauer; Else Marais; Franz Hofmann
Journal:  J Bioenerg Biomembr       Date:  2003-12       Impact factor: 2.945

2.  The analgesic effect of pregabalin in patients with chronic pain is reflected by changes in pharmaco-EEG spectral indices.

Authors:  Carina Graversen; Søren S Olesen; Anne E Olesen; Kristoffer Steimle; Dario Farina; Oliver H G Wilder-Smith; Stefan A W Bouwense; Harry van Goor; Asbjørn M Drewes
Journal:  Br J Clin Pharmacol       Date:  2012-03       Impact factor: 4.335

3.  New Horizons in the development of antiepileptic drugs: Innovative strategies.

Authors:  Wolfgang Löscher; Dieter Schmidt
Journal:  Epilepsy Res       Date:  2006-06       Impact factor: 3.045

4.  The antiallodynic action of pregabalin may depend on the suppression of spinal neuronal hyperexcitability in rats with spared nerve injury.

Authors:  Lei Ding; Jie Cai; Xiang-Yang Guo; Xiu-Li Meng; Guo-Gang Xing
Journal:  Pain Res Manag       Date:  2014-05-21       Impact factor: 3.037

5.  Pregabalin reduces alcohol drinking and relapse to alcohol seeking in the rat.

Authors:  Serena Stopponi; Lorenzo Somaini; Andrea Cippitelli; Giordano de Guglielmo; Marsida Kallupi; Nazzareno Cannella; Gilberto Gerra; Maurizio Massi; Roberto Ciccocioppo
Journal:  Psychopharmacology (Berl)       Date:  2011-09-02       Impact factor: 4.530

6.  Retrospective chart review of duloxetine and pregabalin in the treatment of painful neuropathy.

Authors:  Manoj Mittal; Mamatha Pasnoor; Reddiah B Mummaneni; Saud Khan; April McVey; David Saperstein; Laura Herbelin; Larry Ridings; Yunxia Wang; Mazen M Dimachkie; Richard J Barohn
Journal:  Int J Neurosci       Date:  2011-06-15       Impact factor: 2.292

Review 7.  Pregabalin: as adjunctive treatment of partial seizures.

Authors:  Greg Warner; David P Figgitt
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 8.  Pharmaceutical treatment options for fibromyalgia.

Authors:  Leslie J Crofford
Journal:  Curr Rheumatol Rep       Date:  2004-08       Impact factor: 4.592

9.  Resolution of pregabalin and mirtazapine associated restless legs syndrome by bupropion in a patient with major depressive disorder.

Authors:  Young-Min Park; Heon-Jeong Lee; Seung-Gul Kang; Jae-Hyuck Cho; Leen Kim
Journal:  Psychiatry Investig       Date:  2009-11-19       Impact factor: 2.505

10.  The treatment of generalized anxiety disorder with pregabalin, an atypical anxiolytic.

Authors:  Jeffrey R Strawn; Thomas D Geracioti
Journal:  Neuropsychiatr Dis Treat       Date:  2007-04       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.